Schedule 13D ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares · CUSIP: G1933S101
Event date: 2025-09-26
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Panacea Venture Healthcare Fund II, L.P.Reported CIK 0001869939
Shares: 3,550,000 · Class: 19.4%
- Panacea Venture Healthcare Fund II GP Company, Ltd.
Shares: 3,550,000 · Class: 19.4%
- Panacea Innovation LimitedReported CIK 0002010692
Shares: 3,550,000 · Class: 19.4%
- James HuangReported CIK 0001573160
Shares: 3,661,571 · Class: 19.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193125-25-220898
- Form type
- SCHEDULE 13D
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Sep 26, 2025
- Reporting period
- Sep 26, 2025
- Description
- Schedule 13D beneficial ownership